t
| Date | 5 Apr 2022 |
| Time | 07:00:03 |
| Category | Capital structure |
| ID | 2146H |
EKF Diagnostics Holdings plc
("EKF" or the "Company")
Purchase of Own Shares
Further to the confirmation of its intention to implement a share buyback programme, as set out in its announcement on 29 March 2022, the Company announces that it has purchased a total of 1,000,000 of its ordinary shares at a price of 42.55 pence per share. The ordinary shares purchased will be held in treasury.
Aggregated information
|
Date of purchase |
4 April 2022 |
|
Number of ordinary shares purchased |
1,000,000 |
|
Highest price paid per share |
42.55 |
|
Lowest price paid per share |
42.55 |
|
Volume weighted average price paid |
42.55 |
Transaction details
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018), a detailed breakdown of individual trades is available below:
|
Number of ordinary shares purchased |
Transaction price (GBp) |
Time of transaction |
Trading venue |
|
1,000,000 |
42.55 |
14:45:44 |
AIMX |
Total voting rights
Following the purchase, the Company's total issued share capital will consist of 463,930,564 ordinary shares of 1 pence each ("Ordinary Shares") each carrying one voting right, of which 5,950,000 Ordinary Shares are held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 457,980,564. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
|
Enquiries:
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com) EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:
In May 2021, EKF announced its strategy for delivering growth to 2024 and beyond, and continuing to deliver shareholder value. The strategy for growth can be summarised as:
· continuing innovation in products and services in Point-of-Care, Central Laboratory and Life Sciences leveraging new and existing routes to market and relationships; · investment in expanded production and kitting capabilities to offer a suite of diagnostic Contract Manufacturing solutions to third party businesses; · expansion of CLIA Laboratories Testing offering building on the acquired capabilities in ADL Health; and · identify complementary earnings-enhancing acquisitions with key strategic value.
EKF will also continue to generate enhanced shareholder value through:
· a progressive dividend policy; and · its agreement with Mount Sinai Innovation Partners ("MSIP"), which allows us advanced access to innovative commercial opportunities and where we can build on the ongoing successes of Renalytix plc, Verici Dx plc and Trellus Health plc.
|
|
|||||||||||||||||||
|
|
||||||||||||||||||||
|
|
||||||||||||||||||||
|
|
||||||||||||||||||||
|
|
||||||||||||||||||||
|
|
|
|||||||||||||||||||
|
|
|
|||||||||||||||||||
|
|
|
|||||||||||||||||||
|
|
|
|||||||||||||||||||